Health economic aspects of breast cancer treatment: the compulsory health insurances' view.
Due to the impact of rising expenditures for the delivery of high-standard health care, further efforts supporting evidence-based, cost-efficient and patient-centered management in oncology are advised. This also concerns the treatment of patients with breast cancer. Reimbursement of diagnostic and/or therapeutic innovations in oncologic health care within the compulsory health insurances (CHIs) in Germany requests their evidence-based proof of benefit and medical need. Using selected examples in pharmacotherapy, recommendations to improve outpatient breast cancer care are discussed.
Competence Center Oncology, Medical Services of the Compulsory Health Insurance Funds North Rhine, Düsseldorf, Germany.
Barbara
B
Zimmer
Competence Center Oncology, Medical Services of the Compulsory Health Insurance Funds North Rhine, Düsseldorf, Germany.
Axel
A
Heyll
Breast cancer; Compulsory health care insurance; Cost efficiency; Evidence-based pharmacotherapy